logo-loader
RNS
BioPharma Credit PLC

BioPharma Credit PLC - NEW INVESTMENT OF US$125 MILLION

RNS Number : 8710W
BioPharma Credit PLC
17 March 2026
 

17 March 2026

  

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

NEW INVESTMENT OF US$125 MILLION

 

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investment trust, is pleased to announce that it, through its fully owned subsidiary, together with BioPharma Credit Investments V (Master) LP ("BioPharma-V"), have entered into a new senior secured loan agreement (the "Loan Agreement") with Zenas BioPharma, Inc. ("Zenas").  The Company will invest up to US$125 million and BioPharma-V will invest up to an additional US$125 million in parallel, with the Company acting as collateral agent.

 

Under the Loan Agreement, the Company will invest up to US$125 million across five tranches, subject to customary conditions precedent:

·    Tranche A of US$37.5 million will be funded ten business days following the execution of the Loan Agreement;

·    Tranche B of up to US$37.5 million is available to be drawn by 1 November 2027, of which US$25 million is required to be drawn upon certain regulatory approvals;

·    Tranche C of up to US$12.5 million (less any amounts elected to be and actually drawn under Tranche B in excess of US$25 million) is available to be drawn by 28 April 2028, subject to certain regulatory approvals;

·    Tranche D of US$25 million is available to be drawn by 30 October 2028, subject to achievement of certain milestones in respect of regulatory approvals and certain net sales levels; and

·    Tranche E of US$25 million is available to be drawn by 30 April 2029, subject to achievement of certain milestones in respect of regulatory approvals and certain net sales levels.

The loan will mature in March 2031 and will bear interest at 3-month SOFR plus 5.75 per cent. per annum subject to a 3.25 per cent. SOFR floor. A one-time additional consideration of 2.00 per cent. of Tranche A and US$50 million of Tranche B, and 1.00 per cent. of any amounts in excess of US$50 million of the funding amount for Tranche B and each of Tranche C, D and E, is payable by Zenas upon the funding of each respective tranche.

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases with a  current market capitalization of ~US$1.25 billion (Ticker: ZBIO - NASDAQ).  Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas' lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across the B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The registrational obexelimab Phase 3 INDIGO trial for immunoglobulin G4-related disease (IgG4-RD) met its primary endpoint and all four key secondary endpoints with high statistical significance, and Zenas is on track to submit a BLA for IgG4-RD to the FDA in 2Q26.

 

Enquiries:

 

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

 

Burson Buchanan

Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com

 

Notes to Editors:

 

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCAKABPBBKBOND
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read